Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis

Introduction

Granulomatosis with polyangiitis (GPA) is a clinicopathologic variant of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV). It is characterized by a necrotizing granulomatous inflammation usually involving the upper and lower respiratory tract, a necrotizing vasculitis affecting predominantly small to medium vessels and commonly a necrotizing glomerulonephritis, often in the presence of Proteinase 3 (PR3)-ANCA (Jennette et al., 2012). The aetiology of GPA is unknown; but infections and in particular nasal carriage of Staphylococcus aureus (SA) have been implicated (Tadema, Heeringa & Kallenberg, 2011). SA nasal carriage may trigger GPA through staphylococcal superantigens, molecular mimicry, increased Toll-like receptor signalling in leukocytes and the induction of neutrophil extracellular traps (NETs) (Tadema, Heeringa & Kallenberg, 2011). SA interacts with endothelial, T and B cells creating an inflammatory milieu and activating neutrophils locally responsible of damage by release of proteolytic enzymes and reactive oxygen species (Popa & Tervaert, 2003). SA can evade innate immunity by resisting phagocytosis and can survive inside neutrophils (Foster, 2005). SA can also evade induced immunity since SA can deplete potential antibody-secreting B cells and inhibit proliferation of antigen-specific T cells (Foster, 2005). GPA patients have an abnormal epithelial nasal barrier with an altered basal cytokine expression and a reduced secretion of interleukin-8 upon SA stimulation that could facilitate nasal carriage (Wohlers et al., 2012).

SA permanently colonises the anterior nares of 20% of the population while transient colonisation occurs in another 60% (Peacock, de Silva & Lowy, 2001). In one study, GPA patients have a slightly increased rate of SA nasal carriage (72%), compared to Rheumatoid Arthritis patients (46%) and hospital staff members (58%) (Laudien et al., 2010). The risk of disease relapses in GPA increases with SA nasal carriage (Laudien et al., 2010) and is 7 times higher with chronic SA nasal carriage (Stegeman et al., 1994). Antibiotic prophylaxis with Trimethoprim-sulfamethoxazole (TMP-SMX) can decrease the risk of relapse by 60% and of infections in GPA (Stegeman et al., 1996; Zycinska et al., 2009), although the basis for this is unclear since TMP-SMX antibiotic prophylaxis does not eliminate SA nasal carriage in GPA (Wohlers et al., 2012; Popa et al., 2007).

While immunosuppressive drugs (ID) are the mainstay of therapy in GPA, B cell depleting therapy with rituximab (RTX) has proven very effective in inducing (Jones et al., 2010; Stone et al., 2010) and maintaining remission in GPA (Smith et al., 2012; Cartin-Ceba et al., 2012; Besada, Koldingsnes &h Nossent, 2013). However, side effects of B cell depletion over time such as the reduction in all immunoglobulins (Ig) class levels (Besada, Koldingsnes &h Nossent, 2013) could potentially increase the risk of SA carriage.

Our study investigated if long-term RTX maintenance treatment increases the risk of SA carriage in GPA patients and if SA carriage promoted relapses, infections and/or hypogammaglobulinemia.

Patients and Methods

Since 2001 our vasculitis disease registry (Nordnorsk Vaskulittregister) has collected information on disease presentation and course from patients with an established diagnosis of primary vasculitis followed at the University Hospital of North Norway. All patients gave informed written consent at registry inclusion according to the declaration of Helsinki.

All patients satisfied the American College of Rheumatology 1990 classification and/or Chapel Hill consensus conference criteria (Jennette et al., 1994; Leavitt et al., 1990). Twenty-nine GPA patients from that registry who received long-term RTX treatment with a RTX cumulative dose of 5 g or more before September 2011 were included in the study. Eighty-six percent received RTX for relapse and 14% for new disease. RTX treatment was initiated as two 1-gram infusions 2 weeks apart with co-administration of methylprednisolone 125 mg, paracetamol 1,000 mg and either cetirizine 10 mg or polaramine 4 mg (RA protocol). Due to the observed RTX efficacy and the relapsing nature of GPA, RTX was then re-administered pre-emptively either as 2 g infusion (1 g twice during a fortnight) annually or as 1 g infusion biannually (1 g every 6 months). RTX was added to other ID (other than prednisolone) in 27 patients (93%), while 2 (7%) received RTX in monotherapy. The timing and pace of ID discontinuation was at the discretion of the treating physician, whereas the oral daily prednisolone dose (ODPD) was tapered and discontinued in a controlled manner.

Antibiotic prophylaxis against relapse with TMP-SMX (dose 320 mg of TMP and 1,600 mg of SMX daily) was not blinded and was at the physician’s discretion. Ciprofloxacin (dose ranging from 500 to 1,000 mg daily) was used in case of sulfamide allergy, poor TMP-SMX tolerance or concomitant methotrexate use. Compliance of antibiotic prophylaxis was assessed during patients’ visits. We defined antibiotic prophylaxis as the use of antibiotic prophylaxis for more than 50% of the time during long-term RTX maintenance.

Nasal swabs were performed biannually in one anterior naris by firmly rotating the sterile cotton-swab. Similar to the study of Stegeman et al. (1994), we defined patients with positive SA nasal carriage as either transient or persistent if SA was present in respectively less than 75% and more than 75% of all the nasal swabs. We defined patients as non-SA carriers when none of the nasal swabs grew SA.

Fixed set of blood tests (ANCA levels, quantification of immunoglobulin classes and flow cytometric immunophenotyping of lymphocytes) were performed prior RTX initiation and before each new re-treatment until either 30th September 2011 (closing date of this study) or shortly before the administration of intravenous immunoglobulins (IVIG) due to hypogammaglobulinemia and/or infections. CD4 cell counts and serum total Ig levels taken after the administration of 2 g of RTX and at last visit were included in the study.

Relapses were defined by the recurrence, worsening or first appearance of one or more BVAS items attributable to GPA after remission. Hypogammaglobulinemia was defined as serum total Ig < 6 g/L. Severe infections were defined as if hospitalisation and intravenous antibiotic treatment were necessary, while chronic infections were defined as symptomatic infections mostly localised in the ear-nose-throat (ENT) and respiratory tract, lasting 3 months or more and requiring several antibiotic courses.

Data were analysed with SPSS version 20.0 (SPSS Ltd, Chicago, Ilinois, USA). Descriptive statistics were used to describe SA nasal carriage during RTX maintenance. Continuous variables were expressed in median and range; categorical variables were expressed in number and percentage. Related-samples Wilcoxon signed rank test was used to test for difference between rates of positive SA nasal swabs prior RTX and during maintenance. Chi-square and Kruskal Wallis tests were used appropriately for subgroups analysis concerning SA nasal carriage status. SA nasal carriage, change in SA carriage status and antibiotic prophylaxis during RTX maintenance were analysed by Kaplan–Meier survival curves as risk factors of relapse, infections and RTX discontinuation due to hypogammaglobulinemia. P-values <0.05 were considered significant.

Results

SA nasal carriage

GPA patient characteristics differed in relation to SA nasal carriage. SA non-carriers had less lung involvement (p = 0.047) and seemed to receive higher ODPD at baseline (p = 0.141) compared with patients with either transient or persistent nasal carriage (Table 2). On the other hand, patients with persistent SA nasal carriage had received 55 g of CYC compared with 13 g in the other 2 subgroups (p = 0.163). The use of other ID during RTX treatment was similar within the different SA nasal carriage subgroups (Table 2).

Table 2:

Granulomatosis with polyangiitis patients’ characteristics determined by Staphylococcus aureus nasal carriage during long-term rituximab maintenance.

	No carriage 9 patients	Transient carriage 12 patients	Persistent carriage 8 patients	p-value
Male	5 (56)	5 (42)	5 (62)	0.634
Age at baseline (y)	54	43	44	0.375
Kidney involvement	5(56)	6(50)	6(75)	0.525
Lung involvement	3(33)	10(83)	6(75)	0.047
Orbital-subglottic involvement	4(44)	9(75)	5(63)	0.361
PR3-ANCA	8(89)	10(83)	7(88)	0.414
BVAS at baseline	11	10	10	0.382
RTX maintenance duration (w)	173	182	170	0.305
CYC cumulative dose (g)	13	13	55	0.163
RTX cumulative dose (g)	8	9.5	8	0.468
1 g biannually regimen	6(67)	3(25)	3(38)	0.153
MTX use during RTX	3(33)	4(33)	4(50)	0.711
AZA use during RTX	3(33)	3(25)	2(25)	0.898
MMF use during RTX	1(11)	5(42)	2(25)	0.295
CYC use during RTX	3(33)	3(25)	3(38)	0.891
Total Ig at baseline (g/L)	11	8.5	11	0.278
Total Ig after RTX 2 g (g/L)	8.1	7.5	9.4	0.730
CD4 at baseline (×109/L)	0.39	0.40	0.27	0.538
CD4 after RTX 2g (×109/L)	0.28	0.45	0.39	0.071
Total Ig decline after RTX 2 g (g/L)	3.5	1.4	1.9	0.079
Total Ig overall decline during RTX	5.1	2.5	3.4	0.063
TMP-SMX during RTX	3(33)	3(25)	0	0.212
Ciprofloxacin during RTX	2(22)	3(25)	2(25)	0.987
Severe infections	3(33)	1(8)	3(38)	0.243
Chronic infections	4(44)	5(42)	0	0.082
Relapses	2(22)	3(25)	3(38)	0.754
RTX discontinuation due to hypogammaglobulinemia	4(44)	2(17)	2(25)	0.364

DOI: 10.7717/peerj.1051/table-2

Notes:

AZA

azathioprine

BVAS

Birmingham vasculitis activity score

CD

cluster of differentiation

CYC

cyclophosphamide

Ig

immunoglobulins

MMF

mycophenolate mofetil

MTX

methotrexate

PR3-ANCA

proteinase 3 antineutrophil cytoplasmic antibodies

RTX

rituximab

SA

Staphylococcus aureus

TMP-SMX

trimethoprim-sulfamethoxazole

Results are expressed in medians for continuous variables and in absolute numbers (percentages) for categorical variables. Difference is determined by Kruskal Wallis Test for continuous variables and Chi-square test for categorical variables.

Risk of relapse

During RTX maintenance, 9 relapses occurred in 8 patients (28%) and 2 thirds of the relapses involved the respiratory tract and ENT. Three patients (38%) who relapsed had persistent SA nasal carriage (Table 2). The lone patient who relapsed twice did not carry SA. There was no association between SA nasal carriage and either overall frequency of relapses (p = 0.243) (Table 2) or time-adjusted risk of relapse (p = 0.844) (Fig. 1A). There was no association between change of SA nasal carriage status during RTX and time-adjusted risk of relapse (p = 0.756) (Fig. 2A).

Risk of infections

During RTX maintenance, severe and chronic infections developed in 7 and 9 patients respectively.

Seven patients developed severe infections, but there was no association between SA carriage and the frequency (p = 0.213) (Table 2) or time-adjusted risk (p = 0.144) (Fig. 1B) of severe infections. There was no association between change of SA nasal carriage status during RTX and time-adjusted risk of relapse (p = 0.913) (Fig. 2B).

Nine patients had chronic infections; however, none of these patients had persistent SA nasal carriage (p = 0.082) (Table 2). Patients with persistent SA nasal carriage and patients with an increase of SA nasal carriage status seemed to have a lower time-adjusted risk of developing chronic infections (respectively p = 0.044 and p = 0.125) (Figs. 1C and 2C). Of interest, CD4 cell count seemed to increase in persistent and transient carriers, but seemed to decrease in non-carriers following the first 2 g of RTX (p = 0.071) (Table 2).

Risk discontinuing RTX due to hypogammaglobulinemia

Eight patients discontinued RTX due to hypogammaglobulinemia with a level of serum total Ig of 4.7 (3.5–5.5) g/L. Four patients (50%) had persistent or transient SA nasal carriage, while 4 patients (50%) did not carry SA (Table 2). Patients with transient SA nasal carriage had a tendency to lower time-adjusted risk of discontinuing RTX due to hypogammaglobulinemia, although this was not statistically significant (p = 0.122) (Fig. 1D). Change in SA nasal carriage status during RTX did not influence the risk of discontinuing RTX due to hypogammaglobulinemia (p = 0.474) (Fig. 2D).

Non-SA carriers had a tendency to more profound decline of serum total Ig both after the first 2 g of RTX (p = 0.079) and during RTX maintenance (p = 0.063) compared with patients with either transient or persistent SA carriage (Table 2).

TMP-SMX and ciprofloxacin during RTX

Before RTX initiation, most patients (90%) had received antibiotic prophylaxis with either TMP-SMX or ciprofloxacin at some point during the course of their disease. However, only 16 patients (55%) received TMP-SMX antibiotic prophylaxis during RTX maintenance and just 6 (21%) used TMP-SMX for more than 50% of the time. Similarly, 10 patients (35%) received ciprofloxacin during RTX maintenance and 7 (24%) used it for more than 50% of the time. Two patients (7%) switched from ciprofloxacin to TMP-SMX, while no patients switched from TMP-SMX to ciprofloxacin during RTX maintenance. The first patient switched when methotrexate was discontinued. The other switched with the intention of preventing relapse when mycophenolate mofetil was discontinued (even though the nasal swab was negative). ODPD, CYC cumulative dose and concomitant use of ID during RTX maintenance did not differ between patients receiving either TMP-SMX or ciprofloxacin and patients not receiving antibiotics.

During RTX treatment, none of the six GPA patients who used TMP-SMX for more than 50% of the time had persistent SA nasal carriage and three (50%) were non-SA carriers. In the ciprofloxacin group, 2 (29%) had persistent SA nasal carriage and 2 (29%) were non-SA carriers. Patients who used TMP-SMX for more than 50% of the time during RTX maintenance had an increased risk to hypogammaglobulinemia leading to RTX discontinuation (p = 0.046) (Fig. 3A). On the other hand, none of the patients using ciprofloxacin for more than 50% of the time during RTX maintenance seemed to discontinue RTX due to hypogammaglobulinemia (p = 0.065) (Fig. 3B). There were no significant differences for the risk of severe infections, chronic infections and relapses risks in patients on or off antibiotic prophylaxis (with either TMP-SMX or ciprofloxacin) (data not shown).

Discussion

The rate of persistent SA nasal carriage did not change significantly in GPA patients during long-term RTX treatment, even though SA nasal carriage seemed to increase in patients with transient carriage. Persistent SA nasal carriage was not a risk factor for disease relapses, but was associated with a lower frequency of chronic infections. On the other hand, non-SA carriers seemed to have lower CD4 counts and a steeper decline of total Ig after 2 g of RTX and were more prone to infections and to discontinue RTX due to hypogammaglobulinemia.

Contrary to the seminal study of Stegeman et al. (1994), persistent SA nasal carriage did not increase the risk of relapse in GPA patients whilst on treatment with RTX. This may be due to the lower overall frequency of SA carriers in this cohort since 63% were persistent SA nasal carriers in the Stegeman study (Stegeman et al., 1994), but only 20% and 28% persistently carried SA in our cohort before and during RTX maintenance, respectively. Nasal swabs procedure and inclusion as well as patient selection bias could explain the difference. Nasal swabs were performed unilaterally in our study and bilaterally in the study of Stegeman et al. (1994). Nasal swabs of GPA patients receiving prolonged antibiotics defined as more than 6 weeks were excluded in the study of Stegeman et al. (1994), whereas all nasal swabs in our study were included with or without concomitant antibiotics. Also while Stegeman et al. (1994) enrolled all consecutive patients diagnosed with GPA over a 3.5 years period, our study included consecutive GPA patients receiving long-term RTX maintenance, who had been mostly refractory to conventional therapy.

The frequency of severe infections was equal in persistent and non-SA carriers, but the risk of chronic infections during RTX treatment seemed lower in persistent SA carriers and in patients with increased SA nasal carriage status. In healthy individuals, persistent SA nasal carriers have a higher risk of infection (Johannessen, Sollid & Hanssen, 2012) than transient and non-carriers who eradicate SA faster due to stronger anti-staphylococcal antibodies response (Van Belkum et al., 2009). In our study, non-SA carriers paradoxically seemed to have a more profound decline of total serum Ig and CD4 cell count already after 2 g of RTX, indicating an early effect of RTX on the ability to mount an effective immune response in non-SA carriers.

In healthy individuals, SA carriage also influences the nasal microbiome and inhibits colonisation from other bacteria (Johannessen, Sollid & Hanssen, 2012). Consequently, persistent SA nasal carriage in GPA patients receiving long-term RTX could prevent colonisation from other bacteria and chronic infections due to the continuing interplay between SA and the immune system.

In our selected cohort of closely followed GPA patients, antibiotic prophylaxis was neither universal nor continuous and this reflects the uncertainties regarding this issue (Laudien et al., 2010). TMP-SMX use during RTX maintenance seemed to increase the risk of hypogammaglobulinemia and RTX discontinuation and to decrease persistent SA nasal carriage, compared with ciprofloxacin. While TMP-SMX therapy eliminates neither SA nasal carriage nor endonasal activity in GPA (Laudien et al., 2010), the combination of TMP-SMX and RTX could provoke changes in the nasal epithelial barrier and its microbiome that might be relevant for the course of the disease. Moreover, TMP-SMX could exert an additional anti-inflammatory effect by interfering with the production of reactive oxygen species in neutrophils (Roberts & Curd, 1990). As TMP-SMX decreases the risk of relapse (Stegeman et al., 1996), it could, in addition, increase the risk to discontinue RTX due to hypogammaglobulinemia.

Our retrospective study is limited by its sample size with the low number of events making subgroups analysis prone to type II errors of not detecting significant differences. Patients’ selection with multiple relapses and confounding factors, such as high CYC cumulative dose, could have biased our results and limit their applicability. Despite this, our study is the first that highlights a possible association between SA carriage status, infections and hypogammaglobulinemia during RTX therapy in GPA patients.

In conclusion, SA nasal carriage in GPA patients did not change significantly during long-term RTX maintenance. Non-SA carriers were as likely to have disease flares but were more prone to infections and to discontinue RTX due to hypogammaglobulinemia independently of the CYC cumulative dose. These results suggest that long-term RTX treatment is better tolerated in GPA patients with SA nasal carriage.